There is a two-step proposal process for the MPI/R01 Award.
Please complete the online application https://uic.ca1.qualtrics.com/jfe/form/SV_b30EGRRZvR2MAbX. The application requires a 2-page competitive Letter of Intent (LOI). The LOI should have 0.5” margins and no smaller than Arial 11 point font. It is due by 3:00 PM on September 20, 2018.
The following information should be included:
- Preliminary title (page 1)
- Brief outline of the study plan (goal, hypothesis, specific aims, study methods to be utilized; page 1).
- Complete listing of the investigative team, academic titles, primary departments, and roles (page 2).
- Biosketches and Other Support documentation for Principal Investigators and Project Leaders.
All LOIs will be reviewed by the Associate Directors (who have no conflict of interest related to the proposal and/or PIs). Those who submit an LOI will be notified by September 26 if they are invited to submit a full application (step 2).
For those invited to submit a full application, these are due by October 30, 2018. Please send one PDF file of the application packet via email to Ahlam Al Kodmany, PhD (firstname.lastname@example.org). Applications received by the deadline will be scientifically peer-reviewed by external investigators with substantial expertise in the project area. Notifications of awards will be made by November 15, 2018. The earliest anticipated start date is January 1, 2019, depending on the status of human and animal studies protocol approvals. Note: excessive delay on these approvals does not constitute justification for a no-cost extension.
Two funds will be awarded on a competitive basis for a maximum of $125,000. The maximum period of the award is 12 months. Awardees are required to submit brief quarterly progress reports and a final progress report upon project completion. If timely progress is not made throughout the award year, the award can be terminated upon consultation of the Cancer Center Executive Committee. PIs are expected to seek regulatory approvals in a timely manner because project periods will not be extended. Note that the funding cannot be released until all applicable human and animal subject protocols have been approved and copies sent to the cancer center’s administrative office. All publications derived from this funding must acknowledge cancer center support.
This (work/research/project) was supported by the University of Illinois Cancer Center (UICC-DFA-994000) Program.
The authors gratefully acknowledge use of the services and facilities of the Translational Pathology Core of the University of Illinois Cancer Center (UICC-DFA-994000).